MedTrace Logo

COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV-Infected Patients

NCT03139630 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 193

Last updated 2024-01-30

No results posted yet for this study

Summary

Evaluation of the impact of initiation of protease inhibitor/ritonavir on PCSK9 levels in HIV-infected antiretroviral-naïve patients from the ANRS C09 COPANA cohort.

Conditions

  • HIV Seropositivity
  • Dyslipidemias
  • PCSK9

Sponsors & Collaborators

  • National Agency for Research on AIDS and Viral Hepatitis (ANRS)

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Amgen

    collaborator INDUSTRY

  • Franck Boccara

    lead OTHER

Principal Investigators

  • Franck Boccara, MD, PhD · Saint Antoine University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03139630 on ClinicalTrials.gov